| 000 | 01651 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250514184003.0 | ||
| 264 | 0 | _c20040610 | |
| 008 | 200406s 0 0 eng d | ||
| 022 | _a0891-3668 | ||
| 024 | 7 |
_a10.1097/00006454-200404000-00008 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGolombek, Sergio G | |
| 245 | 0 | 0 |
_aCompliance with prophylaxis for respiratory syncytial virus infection in a home setting. _h[electronic resource] |
| 260 |
_bThe Pediatric infectious disease journal _cApr 2004 |
||
| 300 |
_a318-22 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aHome Care Services _xstandards |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfant |
| 650 | 0 | 4 | _aInfant, Newborn |
| 650 | 0 | 4 | _aInjections, Intramuscular |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aOffice Visits |
| 650 | 0 | 4 | _aPalivizumab |
| 650 | 0 | 4 | _aPatient Compliance |
| 650 | 0 | 4 | _aProbability |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aRespiratory Syncytial Virus Infections _xdrug therapy |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aStatistics, Nonparametric |
| 700 | 1 | _aBerning, Frank | |
| 700 | 1 | _aLagamma, Edmund F | |
| 773 | 0 |
_tThe Pediatric infectious disease journal _gvol. 23 _gno. 4 _gp. 318-22 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/00006454-200404000-00008 _zAvailable from publisher's website |
| 999 |
_c14786554 _d14786554 |
||